Larson, Timothy

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 2,479

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., Seiden, M. V., Liu, M. C., Oxnard, G. R., Klein, E. A., Smith, D., Richards, D., et al. (2020) · Annals of Oncology

Cancer Genomics and DiagnosticsEpigenetics and DNA Methylation

Cited by 1,495

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 237

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Fakih, M., Raghav, K. P. S., Chang, D. Z., Bendell, J. C., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Garbo, L. E., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 72

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

Lenz, H.-J., Parikh, A. R., Spigel, D. R., Cohn, A. L., Yoshino, T., Kochenderfer, M. D., Elez, E., Shao, S. H., Deming, D. A., Holdridge, R. C., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 61